SCHEMBL6706593

SCHEMBL6706593

COC(=O)c1cn(C2CC2)c2c([N+](=O)[O-])c(Cl)c(F)cc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
POLB P06746 2/20 0.46
OPRM1 P35372 2/20 0.46
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
OPRD1 P41143 1/20 0.46
ADRB2 P07550 1/20 0.44
GSK3B P49841 2/20 0.42
TOP2A P11388 5/20 0.42
TOP2B Q02880 5/20 0.42
KCNH2 Q12809 3/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 2/20 0.41
PRKD3 O94806 1/20 0.41
ALOX15 P16050 1/20 0.41
CLK2 P49760 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3123309 0.89 ADRB2 (0.54) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL6213805 0.88 ALDH1A1 (0.56) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL1416412 0.84 ADRB2 (0.49) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL5704356 0.83 GSK3B (0.53) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL6213808 0.83 ALDH1A1 (0.43) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL7030311 0.82 KDM4E (0.51) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL6710683 0.82 KDM4E (0.49) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL27692958 0.82 ALDH1A1 (0.39) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL7029929 0.81 ALDH1A1 (0.50) ALDH1A1POLBOPRM1CHRM2CHRM1
SCHEMBL7646010 0.81 ALDH1A1 (0.47) ALDH1A1POLBOPRM1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040073030-A1 Process for the preparation of quinolone derivatives NATCO PHARMA LIMITED (IN) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040073030-A1 Process for the preparation of quinolone derivatives CBR1, CYP4X1, NRAS ALDH1A1 1601/4885POLB 1574/4885OPRM1 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.